An observational study in Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 6 sites in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-08-02.
Sponsored by Eli Lilly and Company · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company — 4 open to participants now, 6 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Eli Lilly and Company.
Among the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company, this one is one of 7 that started in 2017, is one of 3 observational ones, and was the 42nd registered.
3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →4 of the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States
Ages 18–70
Eli Lilly and Company · Sites in United States, Australia, Belgium and 17 more countries
Ages 1–35
Eli Lilly and Company · Sites in United States, Australia, Belgium and 16 more countries
Ages 1–35
Eli Lilly and Company · Sites in Germany
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 21 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 8 · Phase 3 25 · Phase 4 2
First in 2002; this study’s year is marked. 7 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 79 is below the median of 125 across 792 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 62 across the 72 interventional studies, 28 across the 3 observational. Of the 66 that completed or were terminated, 49 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
4 of the studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07803744Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity | 2026-12 |
| NCT06945406Eli Lilly and CompanyA Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes | 2027-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to estimate missed bolus insulin doses in diabetics. This is a 12-week, single-arm, outpatient, exploratory study with two study periods in Type 1 or Type 2 diabetics, with an investigational reusable injection pen, insulin, and a Continuous Glucose Monitoring (CGM) device.
Type 1 and Type 2 Diabetics
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Women of must meet the following: (Note: females of childbearing potential are defined as those who have experienced menarche and who are NOT permanently sterile or . Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause)
Exclusion Criteria:
Currently undergoing systemic treatment with:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Insulin lispro 100 U/mL (units per millilitre) injected via the pen and they were blinded to CGM device recording as directed in study period 1.
Device: Continuous Glucose Monitoring · Drug: Insulin Lispro
Participants received Insulin lispro 100 U/mL injected via the pen and they were unblinded to CGM device recording as directed in study period 2.
Device: Continuous Glucose Monitoring · Drug: Insulin Lispro
Commercially available
As prescribed.
Average Number of Days Per Month With a Missed Bolus Insulin Dose With Blinded CGM
The average number of days per month with a missed bolus insulin dose was calculated in participants with Type 1 Diabetes or Type 2 Diabetes using blinded CGM measurements and the pen. The time of insulin dosing and glucose excursions were assessed using the display times recorded by the pen and CGM devices, respectively.
Time frame: Week 1 up to 6 weeks
Average Number of Days Per Month With a Missed Bolus Insulin Dose With Unblinded CGM
The average number of days per month with a missed bolus insulin dose was calculated in participants with Type 1 Diabetes or Type 2 Diabetes using unblinded CGM measurements and the pen. The time of insulin dosing and glucose excursions were assessed using the display times recorded by the pen and CGM devices, respectively
Time frame: Week 6 up to 12 weeks
Percentage of Time-in-Range (Glucose >70 and ≤180 Milligrams Per Deciliter) With Blinded CGM
Percentage of time-in-range (glucose \>70 and ≤180 milligrams per deciliter) was calculated in participants with Type 1 Diabetes or Type 2 Diabetes based on blinded CGM data collected in the study period. The time component of the time-in-range statistic was calculated using the display time recorded by the CGM device.
Time frame: Baseline up to 6 weeks
Percentage of Time-in-Range (Glucose >70 and ≤180 Milligrams Per Deciliter) With Unblinded CGM
Percentage of time-in-range (glucose \>70 and ≤180 milligrams per deciliter) was calculated in participants with Type 1 Diabetes or Type 2 Diabetes based on unblinded CGM data collected in the study period. The time component of the time-in-range statistic was calculated using the display time recorded by the CGM device.
Time frame: Week 6 up to 12 weeks
Percentage of Missed Bolus Doses Per Month With Blinded CGM
Percentage of missed bolus doses per month was estimated in participants with Type 1 diabetes or Type 2 diabetes using blinded CGM measurements and the pen.
Time frame: Baseline up to 6 weeks
Percentage of Missed Bolus Doses Per Month With Unblinded CGM
Percentage of missed bolus doses per month was estimated in participants with Type 1 diabetes or Type 2 diabetes using unblinded CGM measurements and the pen.
Time frame: Week 6 up to 12 weeks
Average Number of Missed Bolus Insulin Doses Per Day With Blinded CGM
The average number of missed bolus doses per day was estimated in participants with Type 1 diabetes or Type 2 diabetes using blinded CGM measurements and the pen.
Time frame: Baseline up to 6 weeks
Average Number of Missed Bolus Insulin Doses Per Day With Unblinded CGM
The average number of missed bolus doses per day was estimated in participants with Type 1 diabetes or Type 2 diabetes using unblinded CGM data.
Time frame: Week 6 up to 12 weeks
Average Number of Missed and Suboptimal Bolus Dose (MSBD) Events Per Month With Blinded CGM
The number of Missed and Suboptimal Doses (MSBDs) per month was calculated in participants with Type 1 Diabetes or Type 2 Diabetes as the sum of the identified missed bolus doses and suboptimal bolus doses for each participant for each period.
Time frame: Baseline up to 6 weeks
Average Number of Missed and Suboptimal Bolus Dose (MSBD) Events Per Month With Unblinded CGM
The number of Missed and Suboptimal Doses (MSBDs) per month was calculated in participants with Type 1 Diabetes or Type 2 Diabetes as the sum of the identified missed bolus doses and suboptimal bolus doses for each participant for each period.
Time frame: Week 6 up to 12 weeks
| Milestone | Study Period 1/Study Period 2 |
|---|---|
| Started | 79 |
| Received at least 1 dose of study drug | 78 |
| Completed | 73 |
| Not completed | 6 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Sponsor decision | 1 |
| Withdrew: Lost to follow-up | 1 |
| Milestone | Study Period 1/Study Period 2 |
|---|---|
| Started | 73 |
| Completed | 73 |
| Not completed | 0 |
The average number of days per month with a missed bolus insulin dose was calculated in participants with Type 1 Diabetes or Type 2 Diabetes using blinded CGM measurements and the pen. The time of insulin dosing and glucose excursions were assessed using the display times recorded by the pen and CGM devices, respectively.
| Days per month | Blinded CGM |
|---|---|
| Average Number of Days Per Month With a Missed Bolus Insulin Dose With Blinded CGM | 19.3 ± 6.2 |
The average number of days per month with a missed bolus insulin dose was calculated in participants with Type 1 Diabetes or Type 2 Diabetes using unblinded CGM measurements and the pen. The time of insulin dosing and glucose excursions were assessed using the display times recorded by the pen and CGM devices, respectively
| Days per month | Unblinded CGM |
|---|---|
| Average Number of Days Per Month With a Missed Bolus Insulin Dose With Unblinded CGM | 17.9 ± 5.7 |
Percentage of time-in-range (glucose \>70 and ≤180 milligrams per deciliter) was calculated in participants with Type 1 Diabetes or Type 2 Diabetes based on blinded CGM data collected in the study period. The time component of the time-in-range statistic was calculated using the display time recorded by the CGM device.
| Percentage of time | Blinded CGM |
|---|---|
| Percentage of Time-in-Range (Glucose >70 and ≤180 Milligrams Per Deciliter) With Blinded CGM | 42.7 ± 18.8 |
Percentage of time-in-range (glucose \>70 and ≤180 milligrams per deciliter) was calculated in participants with Type 1 Diabetes or Type 2 Diabetes based on unblinded CGM data collected in the study period. The time component of the time-in-range statistic was calculated using the display time recorded by the CGM device.
| Percentage of time | Unblinded CGM |
|---|---|
| Percentage of Time-in-Range (Glucose >70 and ≤180 Milligrams Per Deciliter) With Unblinded CGM | 49.6 ± 20.0 |
Percentage of missed bolus doses per month was estimated in participants with Type 1 diabetes or Type 2 diabetes using blinded CGM measurements and the pen.
| Percentage of missed bolus dose | Blinded CGM |
|---|---|
| Percentage of Missed Bolus Doses Per Month With Blinded CGM | 25.3 ± 12.3 |
Percentage of missed bolus doses per month was estimated in participants with Type 1 diabetes or Type 2 diabetes using unblinded CGM measurements and the pen.
| Percentage of missed bolus dose | Unblinded CGM |
|---|---|
| Percentage of Missed Bolus Doses Per Month With Unblinded CGM | 23.3 ± 10.2 |
The average number of missed bolus doses per day was estimated in participants with Type 1 diabetes or Type 2 diabetes using blinded CGM measurements and the pen.
| Dose per day | Blinded CGM |
|---|---|
| Average Number of Missed Bolus Insulin Doses Per Day With Blinded CGM | 0.9 ± 0.4 |
The average number of missed bolus doses per day was estimated in participants with Type 1 diabetes or Type 2 diabetes using unblinded CGM data.
| Dose per day | Unblinded CGM |
|---|---|
| Average Number of Missed Bolus Insulin Doses Per Day With Unblinded CGM | 0.9 ± 0.4 |
The number of Missed and Suboptimal Doses (MSBDs) per month was calculated in participants with Type 1 Diabetes or Type 2 Diabetes as the sum of the identified missed bolus doses and suboptimal bolus doses for each participant for each period.
| Dose per month | Blinded CGM |
|---|---|
| Average Number of Missed and Suboptimal Bolus Dose (MSBD) Events Per Month With Blinded CGM | 68.3 ± 24.1 |
The number of Missed and Suboptimal Doses (MSBDs) per month was calculated in participants with Type 1 Diabetes or Type 2 Diabetes as the sum of the identified missed bolus doses and suboptimal bolus doses for each participant for each period.
| Dose per month | Unblinded CGM |
|---|---|
| Average Number of Missed and Suboptimal Bolus Dose (MSBD) Events Per Month With Unblinded CGM | 61.9 ± 22.2 |
Collected over Up To 12 Weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Blinded CGM | 0/78 (0%) | 3/78 (3.8%) | 22/78 (28.2%) |
| Unblinded CGM | 0/73 (0%) | 2/73 (2.7%) | 9/73 (12.3%) |
| Event | Blinded CGM | Unblinded CGM |
|---|---|---|
| Localised infectionInfections and infestations | 0/78 | 2/73 |
| Chest painGeneral disorders | 1/78 | 0/73 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/78 | 0/73 |
| Medical device removalSurgical and medical procedures | 1/78 | 0/73 |
| Event | Blinded CGM | Unblinded CGM |
|---|---|---|
| InfluenzaInfections and infestations | 3/78 | 1/73 |
| Upper respiratory tract infectionInfections and infestations | 3/78 | 0/73 |
| BradycardiaCardiac disorders | 0/78 | 1/73 |
| Chest painGeneral disorders | 0/78 | 1/73 |
| NasopharyngitisInfections and infestations | 1/78 | 1/73 |
| OnychomycosisInfections and infestations | 0/78 | 1/73 |
| Humerus fractureInjury, poisoning and procedural complications | 0/78 | 1/73 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/78 | 1/73 |
| Device damageProduct Issues | 0/78 | 1/73 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/78 | 1/73 |
All enrolled participants who received study drug.
| Age, Continuous(Years) | Overall Study |
|---|---|
| Mean | 48.01 ± 11.71 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 36 |
| Male | 43 |
| Ethnicity (NIH/OMB)(Participants) | Overall Study |
|---|---|
| Hispanic or Latino | 13 |
| Not Hispanic or Latino | 66 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall Study |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 73 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Overall Study |
|---|---|
| United States | 79 |
| Body Mass Index (BMI)(kg/m²) | Overall Study |
|---|---|
| Mean | 30.9 ± 6.1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2017 to primary completion in Jun 2018, 6 months.
Results were first posted in Aug 2019, 1 year 1 month after primary completion.
Of 50 industry-sponsored observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 6 months is below that.
Counting every sponsor, half of 299 studies reached it within 30 months; a quarter within 12 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.